ADHD Medication & Diagnosis Access Watch

Track ADHD treatment access for US patients and parents. Report only confirmed, source-backed items from the last 7 days: shortage status changes for methylphenidate, amphetamine, lisdexamfetamine, atomoxetine and other ADHD products by strength from FDA and ASHP; DEA production quota changes; DEA and HHS telehealth controlled substance prescribing rule changes with effective dates; insurer and PBM formulary, prior authorization and quantity limit changes at UnitedHealthcare, Aetna, Cigna, Elevance, CVS Caremark, Express Scripts and OptumRx; generic launches and price drops; FTC, DOJ and state actions against online ADHD clinics; adult and pediatric diagnosis guideline changes from APSARD and AAP; and Department of Education Section 504 and IEP accommodation guidance. Prefer FDA, ASHP, DEA, insurer, court and professional society sources; ignore supplement marketing. Put the drug or rule first in the title. Use high severity for a new shortage of a top-5 ADHD product, a telehealth rule taking effect within 60 days, or a clinic shutdown affecting active prescriptions. Return no more than 6 findings. Push each as a finding with a title, a two-sentence summary, sections for what changed, who it affects, the date, what to ask a prescriber or pharmacist, and the source link. If nothing qualifies, push nothing and submit the run receipt.